Pharmacokinetics of Posaconazole Within Epithelial Cells and Fungi: Insights Into Potential Mechanisms of Action During Treatment and Prophylaxis

被引:40
作者
Campoli, Paolo [1 ]
Perlin, David S. [4 ,5 ]
Kristof, Arnold S. [2 ,3 ]
White, Theodore C. [6 ]
Filler, Scott G. [7 ]
Sheppard, Donald C. [1 ]
机构
[1] McGill Univ, Dept Microbiol & Immunol, Montreal, PQ, Canada
[2] McGill Univ, Div Resp & Crit Care, Montreal, PQ, Canada
[3] McGill Univ, Meakins Christie Labs, Montreal, PQ, Canada
[4] Publ Hlth Res Inst, Newark, NJ USA
[5] UMDNJ Med Sch, Newark, NJ USA
[6] Univ Missouri Kansas City, Div Cell Biol & Biochem, Kansas City, MO USA
[7] Univ Calif Los Angeles, Med Ctr, Los Angeles Biomed Res Inst Harbor, Div Infect Dis, Torrance, CA 90509 USA
基金
美国国家卫生研究院;
关键词
posaconazole; localization; pharmacokinetics; endoplasmic reticulum; epithelial cells; Aspergillus; postantifungal effect; hydrophobin rodA; ASPERGILLUS-FUMIGATUS; AMPHOTERICIN-B; INTRAPULMONARY PHARMACOKINETICS; STEADY-STATE; FLUCONAZOLE; PHARMACODYNAMICS; ITRACONAZOLE; EFFICACY; CYP51;
D O I
10.1093/infdis/jit358
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Background. The antifungal posaconazole concentrates within host cells and protects against Aspergillus fumigatus. The specific subcellular location of posaconazole and the mechanism by which cell-associated posaconazole inhibits fungal growth remain uncharacterized. Methods. Posaconazole was conjugated with the fluorophore boron-dipyrromethene (BDP-PCZ). A549 pulmonary epithelial cells and A. fumigatus were exposed to BDP-PCZ individually and in coculture. BDP-PCZ subcellular localization and trafficking were observed using confocal microscopy and flow cytometry. Results. BDP-PCZ concentrated within A549 cell membranes, and in particular within the endoplasmic reticulum. Epithelial cell-associated BDP-PCZ rapidly transferred to and concentrated within A. fumigatus cell membranes on contact. BDP-PCZ transfer to conidia did not require phagocytosis and was markedly enhanced by the conidial hydrophobin RodA. Within AF, BDP-PCZ also concentrated in membranes including the endoplasmic reticulum and colocalized with the azole target enzyme CYP51a. Concentration of BDP-PCZ within host and fungal cell membranes persisted for > 48 hours and could be competitively inhibited by posaconazole but not voriconazole. Conclusions. Posaconazole concentrates within host cell membranes and rapidly transfers to A. fumigatus, where it accumulates to high concentrations and persists at the site of its target enzyme. These intracellular and intercellular pharmacokinetic properties probably contribute to the efficacy of PCZ.
引用
收藏
页码:1717 / 1728
页数:12
相关论文
共 30 条
[1]   Comparative clinical effectiveness of prophylactic voriconazole/posaconazole to fluconazole/itraconazole in patients with acute myeloid leukemia/myelodysplastic syndrome undergoing cytotoxic chemotherapy over a 12-year period [J].
Ananda-Rajah, Michelle R. ;
Grigg, Andrew ;
Downey, Maria T. ;
Bajel, Ashish ;
Spelman, Tim ;
Cheng, Allen ;
Thursky, Karin T. ;
Vincent, Janette ;
Slavin, Monica A. .
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2012, 97 (03) :459-463
[2]  
[Anonymous], 2008, APPROVED STANDARD M3
[3]   The innate immune response to Aspergillus fumigatus [J].
Balloy, Viviane ;
Chignard, Michel .
MICROBES AND INFECTION, 2009, 11 (12) :919-927
[4]   Interactions of Aspergillus fumigatus with endothelial cells:: internalization, injury, and stimulation of tissue factor activity [J].
Bezerra, LML ;
Filler, SG .
BLOOD, 2004, 103 (06) :2143-2149
[5]   Concentration of Antifungal Agents within Host Cell Membranes: a New Paradigm Governing the Efficacy of Prophylaxis [J].
Campoli, P. ;
Al Abdallah, Q. ;
Robitaille, R. ;
Solis, N. V. ;
Fielhaber, J. A. ;
Kristof, A. S. ;
Laverdiere, M. ;
Filler, S. G. ;
Sheppard, D. C. .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2011, 55 (12) :5732-5739
[6]   Structural Characterization of CYP51 from Trypanosoma cruzi and Trypanosoma brucei Bound to the Antifungal Drugs Posaconazole and Fluconazole [J].
Chen, Chiung-Kuang ;
Leung, Siegfried S. F. ;
Guilbert, Christophe ;
Jacobson, Matthew P. ;
McKerrow, James H. ;
Podust, Larissa M. .
PLOS NEGLECTED TROPICAL DISEASES, 2010, 4 (04)
[7]   Steady-State Intrapulmonary Pharmacokinetics and Pharmacodynamics of Posaconazole in Lung Transplant Recipients [J].
Conte, John E., Jr. ;
DeVoe, Catherine ;
Little, Emily ;
Golden, Jeffrey A. .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2010, 54 (09) :3609-3613
[8]   Intrapulmonary Pharmacokinetics and Pharmacodynamics of Posaconazole at Steady State in Healthy Subjects [J].
Conte, John E., Jr. ;
Golden, Jeffrey A. ;
Krishna, Gopal ;
McIver, Marina ;
Little, Emily ;
Zurlinden, Elisabeth .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2009, 53 (02) :703-707
[9]   Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia [J].
Cornely, Oliver A. ;
Maertens, Johan ;
Winston, Drew J. ;
Perfect, John ;
Ullmann, Andrew J. ;
Walsh, Thomas J. ;
Helfgott, David ;
Holowiecki, Jerzy ;
Stockelberg, Dick ;
Goh, Yeow-Tee ;
Petrini, Mario ;
Hardalo, Cathy ;
Suresh, Ramachandran ;
Angulo-Gonzalez, David .
NEW ENGLAND JOURNAL OF MEDICINE, 2007, 356 (04) :348-359
[10]   Posaconazole Exposure-Response Relationship: Evaluating the Utility of Therapeutic Drug Monitoring [J].
Dolton, Michael J. ;
Ray, John E. ;
Marriott, Deborah ;
McLachlan, Andrew J. .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2012, 56 (06) :2806-2813